FDA De Novo Submission: Classification Request Process and Timeline
An FDA De Novo submission asks FDA to classify a new, low to moderate risk device into Class I or Class II when there is no legally marketed predicate for a 510(k). A granted De Novo creates a new classification regulation, and your device can then serve as a predicate for future 510(k)s. I3CGLOBAL prepares De Novo requests for medical device, IVD and software manufacturers worldwide.
The basics
What Is an FDA De Novo Submission?
The FDA De Novo classification request is a marketing pathway for novel devices. By law, a device with no predicate is automatically Class III, which would normally mean a premarket approval (PMA). A De Novo submission lets you show that general controls, or general and special controls, give reasonable assurance of safety and effectiveness, so FDA can place the device in Class I or Class II instead.
Eligibility depends on the level of risk, FDA precedent and your ability to characterise and mitigate the risks of the device. When FDA grants the request, it publishes a new classification regulation. Devices classified this way may be marketed immediately and, where appropriate, used as predicates for future FDA 510k submission filings.
The De Novo program is part of FDA’s medical device classification system and is often used for digital health, diagnostics and new technologies.
Listen: FDA De Novo classification in 7 minutes
A short audio overview of the De Novo classification pathway.
Choosing a pathway
De Novo vs 510(k) vs PMA: Which Pathway Fits?
The right pathway depends on whether a predicate exists and how high the risk is. Use this comparison before you commit to testing.
| Pathway | When to use it | Outcome |
|---|---|---|
| 510(k) | A legally marketed predicate exists with the same intended use and similar technology | Clearance based on substantial equivalence |
| De Novo | No predicate exists, and the risk is low to moderate and can be controlled | Grant, with a new Class I or II regulation |
| PMA | High-risk Class III device, or risks that general and special controls cannot address | Approval based on valid scientific evidence of safety and effectiveness |
To check whether a predicate exists, search FDA’s Product Classification, 510(k) and De Novo databases. Our predicate device selection service documents this search.
Routes to FDA
Two Ways to Submit a De Novo Request
Option 1: after a 510(k) NSE decision
You submit a 510(k), FDA finds the device not substantially equivalent (NSE) because there is no predicate, and you then file a De Novo request.
Option 2: direct De Novo
You decide that no legally marketed device can serve as a predicate and submit the De Novo directly, without a 510(k) first. This is the faster and more common route today.
FDA recommends a Pre-Submission (Q-Sub) before a De Novo, to agree the classification approach, special controls and testing plan with the review division.
Want more detail on FDA De Novo and 510k services?
Submit your email for details in 2 minutes. View our Privacy Policy.
Content and format
What Does a De Novo Submission Contain?
Since 1 October 2025, every De Novo request must be sent electronically as an eSTAR through the CDRH Portal, unless FDA grants an exemption. The structure is close to a 510(k), but the arguments are different.
Not required
A 510(k) summary or statement, and a substantial equivalence comparison, because the request does not claim equivalence to a predicate.
Classification recommendation
The class you propose (I or II), with the reasons, and the search showing that no predicate exists.
Risks and mitigations
Every risk to health, with the general and special controls that mitigate each one.
Proposed special controls
For Class II, draft special controls such as performance testing, labeling or software requirements.
Benefit-risk assessment
A benefit-risk determination supported by bench, animal or clinical data.
Device data
Device description, labeling, biocompatibility, electrical safety, software and performance testing.
The slides above summarise the De Novo submission content and process.
Process and timeline
FDA De Novo Submission Process and Timeline
- 1. Pre-Submission (recommended)Agree the classification, special controls and test plan with FDA before you file.
- 2. eSTAR submission (day 0)Pay the De Novo user fee and submit through the CDRH Portal. FDA assigns a number starting with DEN and sends an acknowledgement.
- 3. Acceptance review (within 15 days)FDA runs the technical screening of the eSTAR. Incomplete requests are placed on hold until the missing items are received.
- 4. Substantive reviewThe review team checks that no predicate exists and assesses risks, controls and data, interacting with you on minor issues.
- 5. Additional information requestMajor deficiencies are sent in an AI letter. The review clock stops, and you have 180 calendar days to respond. No extensions are granted, and a request without a response is considered withdrawn.
- 6. DecisionFDA aims to decide within 150 review days, not counting hold time. See FDA’s De Novo classification request page.
In our experience, a De Novo submission takes about 12 to 18 months from the start of preparation to a decision, depending on testing and the number of FDA questions.
Decision
What Happens After a De Novo Decision?
Granted
The device is classified into Class I or II and can be marketed. FDA publishes a new classification regulation and product code, and the device can serve as a predicate for future 510(k)s. Then complete establishment registration and device listing.
Declined
The device remains Class III and cannot be legally marketed. Options are a new De Novo with better data, or a PMA.
Withdrawn
A request is withdrawn if you send FDA a written notice, or if you do not answer an additional information request within 180 days.
After a grant, the special controls in the new regulation apply to every later device of that type, including competitors that use your device as a predicate. Next step: FDA establishment registration and device listing.
Cost
How Much Does an FDA De Novo Submission Cost?
The FDA user fee is fixed for each fiscal year and is much higher than the 510(k) fee. Testing and consulting costs depend on the device.
FDA user fee
USD 191,020Standard De Novo fee, 1 October 2026 to 30 September 2027.
Small business
USD 47,755For businesses with FDA small business status, gross receipts of USD 100 million or less.
Review goal
150 daysFDA review days, excluding time on hold for additional information.
Source: FDA medical device user fee rates for FY 2027. For consulting fees, see FDA 510k and De Novo fees or the FDA 510k cost calculator.
Practical guide
How to Prepare a Strong De Novo Submission
A strong De Novo submission does three things: it proves that no predicate exists, it shows which risks the device presents, and it proposes controls that reduce each risk to an acceptable level. FDA uses your request to write a new classification regulation, so the reviewer is checking whether your proposal could work as a rule for every future device of the same type. The eight steps below follow the order in which we build a De Novo request with our clients, and each one names the evidence an FDA reviewer expects to find in the file.
- 1. Document why no predicate existsSearch the FDA 510(k), De Novo and product classification databases for devices with the same intended use and technology, and record the search terms, dates and results. FDA expects a clear explanation of why no legally marketed device can serve as a predicate. A weak search is one of the first things a reviewer questions.
- 2. Write a precise intended use and indicationsThe classification FDA creates is built around your intended use. Define the patient population, the clinical condition, the user and the environment of use. Indications that are too broad attract more risks, more special controls and more testing; indications that are too narrow can limit the market for years.
- 3. Identify the risks to healthList every risk to health the device could present, such as electrical hazards, biocompatibility, software failure, misdiagnosis or user error. Base the list on your ISO 14971 risk management file, not on a generic template, because each risk must be linked to a mitigation in the next step.
- 4. Propose the class and special controlsFor a Class II device, propose special controls that mitigate each identified risk: performance testing, biocompatibility, software validation, electrical safety and EMC, sterility, shelf life and labeling. For a Class I device, explain why general controls alone give reasonable assurance of safety and effectiveness. Include a proposed classification name and regulation text.
- 5. Build the benefit-risk argumentShow that the probable benefits outweigh the probable risks for the intended population, using FDA’s benefit-risk factors: the type, size and duration of benefit, the likelihood and severity of harm, patient perspectives and the availability of alternative treatments.
- 6. Generate the performance dataTesting for a De Novo submission uses the same recognised standards as a 510(k) for a similar device. Electrical and software-driven products follow the IEC 60601 and IEC 62304 route described in our active device 510k guide, while implants, disposables and instruments follow the bench, biocompatibility and sterilisation route in the non-active device 510k flow chart. Clinical data is needed only when bench and analytical data cannot answer the open questions.
- 7. Agree the plan in a Pre-SubmissionSend FDA your proposed classification, risk list, special controls and test plan in a Q-Sub before you run expensive studies. A Pre-Submission has no FDA user fee, and written feedback on the test plan is the most reliable way to avoid additional information requests later.
- 8. Assemble the eSTAR and check itComplete every eSTAR section, attach the full test reports rather than summaries, and make the labeling match the indications word for word. Check that each risk in your list points to a special control and to the evidence that meets it, because this traceability is what the reviewer follows.
Common reasons De Novo requests are delayed
- A predicate search that misses a cleared device with the same intended use, which leads FDA to ask why a 510(k) was not filed instead.
- Risks listed without a matching special control, or special controls with no test data to show they are met.
- Test reports to superseded standards, or summaries without the full protocol and results.
- Labeling claims that go beyond the indications for use supported by the data.
- No Pre-Submission, so the test plan is questioned for the first time during the substantive review.
Each of these adds an additional information request, and the review clock stops while you respond. Planning the De Novo submission around the risk-to-control traceability from the start is the most effective way to keep the review close to the 150-day FDA goal.
What a granted De Novo means after clearance
When FDA grants a De Novo, it creates a new classification regulation and product code for the device type, and your device becomes the first legally marketed device of that type. From then on, competitors can reach the market through a 510(k) that names your device as the predicate and meets the same special controls you proposed. This is why the special controls deserve careful thought: they set the bar for every later device of the same type, including your own next generation, which will usually follow the 510(k) route rather than a second De Novo submission.
How we help
FDA De Novo Submission Services From I3CGLOBAL
Securing an FDA De Novo classification is essential for innovative devices. Our QARA team plans the classification strategy, identifies the test requirements, prepares the request and manages FDA questions until the decision.
Pathway assessment
Predicate search and a written rationale for De Novo, 510(k) or PMA.
Pre-Submission
Q-Sub package with questions on classification, special controls and testing.
Risk and controls
Risk analysis with mitigations and drafted special controls.
Test planning
Bench, biocompatibility, electrical safety, software and clinical evidence plans.
eSTAR preparation
Complete De Novo request compiled and validated in eSTAR.
Review support
Responses to FDA questions and additional information requests until the decision.
For other pathways, see our FDA 510k consultants.
Work with I3CGLOBAL
Planning an FDA De Novo Submission?
Tell us about your device and its intended use. We will confirm whether De Novo is the right pathway and send a fixed-fee proposal.
- Pathway and predicate assessment
- Pre-Sub and special controls
- eSTAR De Novo request
Request your proposal
Share your device and intended use, and we will prepare a fixed-fee De Novo submission proposal.
FAQs
FDA De Novo Submission: Frequently Asked Questions
What is an FDA De Novo submission?
An FDA De Novo submission is a request to classify a novel, low to moderate risk device into Class I or Class II when no legally marketed predicate exists. A granted De Novo creates a new classification regulation.
What is the difference between De Novo and 510(k)?
A 510(k) shows substantial equivalence to an existing predicate. A De Novo is used when there is no predicate, and it shows that general or special controls are enough to make the new device type safe and effective.
How much is the FDA De Novo fee?
For fiscal year 2027 (1 October 2026 to 30 September 2027), the De Novo user fee is USD 191,020, or USD 47,755 for a qualified small business.
How long does a De Novo submission take?
FDA’s goal is a decision within 150 review days, excluding time on hold. Including preparation and FDA questions, most De Novo projects take about 12 to 18 months.
Is eSTAR required for a De Novo request?
Yes. Since 1 October 2025, De Novo requests must be submitted electronically as an eSTAR through the CDRH Portal, unless FDA grants an exemption.
Can a De Novo device be used as a predicate?
Yes. Once FDA grants the De Novo, the device can serve as a predicate for future 510(k) submissions for the same device type.
What happens if a De Novo request is declined?
The device remains Class III and cannot be legally marketed. You can submit a new De Novo with better data or follow the PMA pathway.
Which databases help confirm that De Novo is the only choice?
Search FDA’s Product Classification database, the 510(k) database and the De Novo database (Device Classification Under Section 513(f)(2)) to confirm that no suitable predicate exists.
